| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - The purpose of the present study was to investigate the association between left ventricular systolic function and the response to clopidogrel. METHODS: The efficacy of clopidogrel was measured by the vasodilator-stimulated phosphoprotein phosphorylation 20 ± 4 h after 600 mg of clopidogrel. High on-clopidogrel platelet reactivity (HCPR) was defined as a platelet reactivity index (PRI) >=50 %. The 30-day combined incidence of death, non-fatal acute coronary syndrome, re-percutaneous coronary intervention (PCI), stent thrombosis, and stroke was also investigated. RESULTS: The study group consisted of 519 patients undergoing PCI. The values (mean and 95 % confidence interval) of the PRI were as follows: 40.4 % (37.8-43.0) in patients with left ventricular ejection fraction (LVEF) >50 %, 42.4 % (39.3-45.6) in patients with LVEF 35-50 %, and 46.7 % (40.6-52.9) in patients with LVEF <35 % (p = 0.013). The proportions of patients with HCPR were 35.9 % in patients with LVEF >=35 and 51.9 % in patients with LVEF <35 % (p = 0.022). After adjustment for variables that significantly influenced clopidogrel efficacy, LVEF <35 % was found to be independently associated with HCPR (p = 0.039). The 30-day combined clinical endpoint occurred in 18 % of patients with LVEF <35 % and in 7.3 % of patients with LVEF >=35 % (p = 0.026). The 30-day incidence of all-cause mortality was 14 % in patients with LVEF <35 and 1.0 % in patients with LVEF >=35 % (p < 0.001). CONCLUSION: An LVEF <35 % was found to be independently associated with HCPR.
- The purpose of the present study was to investigate the association between left ventricular systolic function and the response to clopidogrel. METHODS: The efficacy of clopidogrel was measured by the vasodilator-stimulated phosphoprotein phosphorylation 20 ± 4 h after 600 mg of clopidogrel. High on-clopidogrel platelet reactivity (HCPR) was defined as a platelet reactivity index (PRI) >=50 %. The 30-day combined incidence of death, non-fatal acute coronary syndrome, re-percutaneous coronary intervention (PCI), stent thrombosis, and stroke was also investigated. RESULTS: The study group consisted of 519 patients undergoing PCI. The values (mean and 95 % confidence interval) of the PRI were as follows: 40.4 % (37.8-43.0) in patients with left ventricular ejection fraction (LVEF) >50 %, 42.4 % (39.3-45.6) in patients with LVEF 35-50 %, and 46.7 % (40.6-52.9) in patients with LVEF <35 % (p = 0.013). The proportions of patients with HCPR were 35.9 % in patients with LVEF >=35 and 51.9 % in patients with LVEF <35 % (p = 0.022). After adjustment for variables that significantly influenced clopidogrel efficacy, LVEF <35 % was found to be independently associated with HCPR (p = 0.039). The 30-day combined clinical endpoint occurred in 18 % of patients with LVEF <35 % and in 7.3 % of patients with LVEF >=35 % (p = 0.026). The 30-day incidence of all-cause mortality was 14 % in patients with LVEF <35 and 1.0 % in patients with LVEF >=35 % (p < 0.001). CONCLUSION: An LVEF <35 % was found to be independently associated with HCPR. (en)
|
| Title
| - Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity
- Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity (en)
|
| skos:prefLabel
| - Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity
- Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity (en)
|
| skos:notation
| - RIV/00216208:11120/14:43908414!RIV15-MSM-11120___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/14:43908414
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Toxicology; Pharmacology; Pharmacotherapy; Cardiology (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - American Journal of Cardiovascular Drugs
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Widimský, Petr
- Moťovská, Zuzana
- Doktorová, Magdalena
- Ondráková, Martina
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| - 10.1007/s40256-014-0074-3
|
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)